Long term survival after radiofrequency ablation for kidney cancer

A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]

read more

Bone-targeted therapies may improve survival in metastatic kidney cancer patients

A recent study published in the journal Translational Oncology suggests that bone-targeted therapies, such as denosumab and zoledronic acid may have a continued role in the treatment of patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy and immunotherapy. Bone is the second most common site of metastasis in patients with […]

read more

Body mass index may impact survival in patients with kidney cancer

A recent paper published in the journal Lancet Oncology provides evidence that obese individuals with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) achieved longer overall survival than patients of normal weight. The study investigated select groups of ccRCC patients and evaluated overall survival and genetic differences in the primary tumour and the […]

read more

Radiofrequency ablation and systemic treatment for kidney cancer lung metastases

A recent study published in BMC Cancer reports on the safety and efficacy of radiofrequency ablation (RFA) for local treatment of renal cell carcinoma (RCC) lung metastases in combination with systemic treatments. The researchers treated 100 lung metastases in 53 patients with RFA. Median follow-up time was 61 months and 5-year overall survival was 62%. Median […]

read more

Association of anxiety and depression with outcomes for kidney cancer patients undergoing nephrectomy

A recent retrospective study of 1990 adults who had a radical or partial nephrectomy for clear cell renal cell carcinoma (RCC) looked at the association between anxiety or depression and survival. Patients with anxiety or depression prior to or at the time of surgery (197 patents, 10%) had significantly more complications 30 days after surgery. […]

read more

The effect of weight change on kidney cancer patients treated with targeted therapy

A recent retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) and on first- or second-line targeted therapy clinical trials showed that patients who experience weight loss during treatment have worse outcomes compared with patients with stable weight at 6 and 12 weeks of treatment. Weight loss at 6 weeks after the start […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Prognostic implications of aquaporin 9 expression in kidney cancer

Water channel proteins, or aquaporins (AQPs) have been found in large amounts in tumour samples and have a role in the progression of cancer. This study looked at the messenger RNA (mRNA) expression for AQP9 and how this related to survival for patients with renal cell carcinoma (RCC). The data for this study came from […]

read more

Small primary tumour size and prognosis

A recent study published in European Urology Oncology this month looked at the impact of tumour size on survival in patients with metastatic renal cell carcinoma (RCC) who had had surgery to remove their tumour. The researchers interrogated two databases from America, looking at tumour size and overall survival. Data from over 1,000 patients were […]

read more

Real world use of targeted therapies in war veterans with kidney cancer

A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]

read more
Showing 1 to 10 of 86 results
  TOP